Neurocrine Biosciences, Inc. (NBIX) Q3 2018 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Down 4.56%

Neurocrine Biosciences reported better-than-expected earnings per share, but the stock fell by 4.56% following the announcement. The decline may be attributed to the lack of revenue information and guidance, leaving investors uncertain about future performance. Management's cautious tone could also have contributed to the stock's negative reaction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.52	N/A	+11.91%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their financial performance. They emphasized the importance of their ongoing projects.

Management expressed satisfaction with the EPS performance despite challenges.

They highlighted ongoing projects but did not provide specific revenue figures.

Neurocrine Biosciences Beats on EPS, Stock Down 4.56%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Down 4.56%

Key numbers

Management commentary